Lota S. Zoth

Lota S. Zoth, CPA, has served as a member of NewLink Genetics’ Board (now Lumos Pharma) and Chair of the Audit Committee since November 2012. Ms. Zoth currently also serves on the Board of Directors of two other biopharmaceutical organizations, including Zymeworks Inc. (NYSE:ZYME) – Board Chair and Audit Committee Chair, and Inovio Pharmaceuticals (NASDAQ:INO) – Audit Committee Chair. Ms. Zoth has served on several other biopharmaceutical boards, including: Orexigen Therapeutics, Inc., Aeras, Circassia Pharmaceuticals plc, Spark Therapeutics, Inc., Hyperion Therapeutics, Inc. and Ikaria, Inc.. Prior to her board service, Ms. Zoth served as Chief Financial Officer of MedImmune, Inc. and was a financial executive at several companies, including Sodexho Marriott Services, Inc., PSINet Inc., Marriott International, Inc., and PepsiCo, Inc. Ms. Zoth began her career as an auditor at Ernst & Young, LLP. Ms. Zoth received a BBA in accounting, summa cum laude, from Texas Tech University.